BioSpace News Archive

SK Life Science, Inc. today announced the U.S. Food and Drug Administration (FDA) approved two new administration options of XCOPRI® (cenobamate tablets) CV, an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, which can now be crushed and mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube.

Edesa Biotech, Inc. announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for April 16-17, 2024 in Toronto, Ontario.

EMulate Therapeutics, Inc. (EMulate) announces the peer-reviewed publication titled, “Evaluation of the EMulate Therapeutics’ Ultra-Low Radiofrequency Energy (ulRFE®) Device in Murine Model of Glioblastoma (GBM)” in BMC Bioelectronic Medicine.

Kane Biotech Inc. announces that it has reached an agreement in principle for the sale of its entire interest in STEM Animal Health Inc. to a third party multi-national pharmaceutical company on a cash-free debt-free basis for US $8,000,000, subject to adjustments in accordance with the terms of the agreement in principle, as well as other consideration including the net cash held in STEM and a working capital adjustment.

The Milken Institute announced its program agenda and initial list of distinguished speakers for its 2024 Global Conference, taking place from May 5 – 8 at The Beverly Hilton in Los Angeles, CA.

The small cell lung cancer therapeutics market size was valued at 5.75 billion in 2023 and is anticipated to reach around 16.33 billion by 2032, expanding at a CAGR of 12.3% from 2023 to 2032.

Marius Pharmaceuticals today announced published results from MRS-TU-2019EXT, a six-month clinical trial of 139 men with low testosterone studying the safety and efficacy of its oral testosterone replacement therapy, KYZATREX® (testosterone undecanoate) CIII Capsules in adult men with conditions associated with a deficiency or absence of endogenous testosterone.

Waters Corporation (NYSE:WAT) will hold its Q1 2024 financial results conference call live on Tuesday, May 7th, 2024 at 8:00 a.m. Eastern Time.

Enlivex Therapeutics Ltd. today announced that it will host a conference call and webcast on April 12, 2024, at 8:30am ET (15:30 IL time) to discuss topline results from its Phase II trial of Allocetra™ in patients with sepsis, in which 120 patients enrolled.

Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that it has commenced an underwritten public offering of $125 million of its common stock and, in lieu of common stock, in the case of certain investors, pre-funded warrants to purchase shares of its common stock.